Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia

European Journal of Haematology

Volumn 57, Issue 1, 1996, Pages 46-53

  Itala M ^a   Vainio, O ^a   Remes, K ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemiluminescence; Chemotaxis; CLL; Infections

Indexed keywords

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; GRANULOCYTE FUNCTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; INFECTION SENSITIVITY; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PHAGOCYTOSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029901196     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00489.x     Document Type: Article

References (30)

1. GALE RP, CALIGARIS-CAPPIO F, DIGHIERO G, KEATING M, MONTSERRAT E, RAI K, FOR THE INTERNATIONAL WORKSHOP ON CHRONIC LYMPHOCYTIC LEUKEMIA. Recent progress in chronic lymphocytic leukemia. Leukemia 1995: 8: 1610-1614.
2. BUNCH C, CHAPEL H, GALE RP. Infectious complications in chronic lymphocytic leukaemia. In Polliack A, Catovsky D, eds. Chronic lymphocytic leukaemia. London: Harwood Academic: 1988: 249-262.
3. CHAPEL HM, BUNCH C. Mechanisms of infection in chronic lymphocytic leukemia. Semin Hematol 1987: 24: 291-296.
4. ITÄLÄ M, HELENIUS H, NIKOSKELAINEN J, REMES K. Infections and serum IgG levels in patients with chronic lymphocytic leukaemia. Eur J Haematol 1992: 48: 266-270.
5. DIGHIERO G, TRAVADE P, CHEVRET S, FENAUX P, CHASTANG C, BINET J-L. B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991: 78: 1901-1914.
6. PRIETO A, GARCIA-SUAREZ J, REYES E, LAPEÑA P, HERNANDEZ M, ALVAREZ-MON M. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals. Exp Hematol 1993: 21: 1563-1569.
7. MATZNER Y. Neutrophil function in hematological neoplasia. Leuk Lymphoma 1991: 4: 9-15.
8. KANSU E, AKALIN E, CIVELEK C, TEKESIN O, LALELI Y, FIRAT D. Serum bactericidal and opsonic activities in chronic lymphocytic leukemia and multiple myeloma. Am J Hematol 1986: 23: 191-196.
9. NAGLER A, OBEDEANU N, TATARSKY I, HOCHERMAN I, MERZBACH D, CARTER A. Chemiluminescence response of polymorphonuclear leukocytes to serum opsonized zymosan - a predictive parameter for infections and prognosis in multiple myeloma patients. Clin Lab Haemat 1988: 10: 365-375.
10. JAYASWAL U, ROPER S, ROATH S. Impairment of neutrophil chemotaxis by serum from patients with chronic lymphoproliferative disease. J Clin Pathol 1983: 36: 449-453.
11. SIEGBAHN A, VENGE P, NILSSON K, SIMONSON B. Identification of a chemokinetic inhibitor in serum from patients with chronic lymphocytic leukemia. Scand J Haematol 1982: 28: 122-131.
12. SIEGBAHN A, VENGE P, NILSSON K. Cellular origin of the chemokinetic inhibitor of polymorphonuclear leukocytes found in sera from patients with chronic lymphocytic leukemia. Scand J Haematol 1983: 31: 184-192.
13. SIEGBAHN A, SIMONSSON B, VENGE P. The chemokinetic inhibitory factor (CIF) in serum of CLL patients: correlation with infection propensity and disease activity. Scand J Haematol 1985: 35: 80-87.
14. SIEGBAHN A, NILSSON K, VENGE P. The chemokinetic inhibitory factor derived from chronic lymphocytic leukaemia cells. Partial purification and characterization of a new lymphokine. Scand J Immunol 1986: 23: 15-23.
15. PEREZ HD, LIPTON M, GOLDSTEIN IM. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest 1978: 62: 29-38.
16. ROBINSON P. WAKERFIELD D, BREIT SN, EASTER JF, PENNY R. Chemiluminescent response to pathogenic organisms: normal human polymorphonuclear leukocytes. Infect Immun 1984: 43: 744-752.
17. DAVEY FR, NELSON DA. Phagocyte function tests. In: HENRY JB, ed. Clinical diagnosis and management. Pa: WB Saunders Co: 1984: 857-859.
18. ESKOLA J, NURMI T, RUUSKANEN O. Defective B cell function associated with inherited interstitial deletion of the short arm of the X chromosome. J Immunol 1983: 131: 1218-1221.
19. PELLER S, KAUFMAN S. YONA R. Functions of polymorphonuclear (PMN) leukocytes of patients with lymphoproliferative diseases. Immunol Lett 1985: 10: 53-56.
20. BONVINI E, ZEREGA R, MINERVINI F, DALLEGRI F, PATRONE F, SACCHETTI C. Neutrophil function in patients with lymphoproliferative disorders. Haematologica 1983: 68: 38-45.
21. VON FLIEDNER V, SALVATORI V, HIGBY DJ, STUTZMAN L, PARK BH. Polymorphonuclear neutrophil function in malignant lymphomas and effects of splenectomy. Cancer 1980: 45: 469-475.
22. WARD PA, BERENBERG JL. Defective regulation of inflammatory mediators in Hodgkin's disease. N Engl J Med 1974: 290: 76-80.
23. ZIELINSKI CC, LANZER G, LUDWIG HP. Defects of leukocyte locomotion in multiple myeloma. J Clin Lab Immunol 1982: 7: 111-114.
24. LOMAS DA, CHAMBA MI, STOCKLEY RA. The effect of in vitro and in vivo dexamethasone on human neutrophil function. Agents Actions 1991: 33: 279-285.
25. IUS/WHO WORKING GROUP. Laboratory investigations in clinical immunology: methods, pitfalls, and clinical indications. Clin Immunol Immunopathol 1988: 49: 478-497.
26. KUNICKA JE, TALLE MA, DENHARDT GH, BROWN M, PRINCE LA, GOLDSTEIN G. Immunosuppression by glucocorticoids: Inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol 1993: 149: 39-49.
27. SMITH JL, COWLING DC, BARKER CR. Response of lymphocytes in chronic lymphocytic leukaemia to plant mitogens. Lancet 1972: i: 229-233.
28. JOHNSTONE AP, JENSENIUS JC, MILLARD RE. HUDSON L. Mitogen-stimulated immunoglobulin production by chronic lymphocytic leukaemic lymphocytes. Clin Exp Immunol 1982: 47: 697-705.
29. KUREC AS, DAVEY FR. Impaired synthesis of immunoglobulin in patients with chronic lymphocytic leukemia. Am J Hematol 1987: 25: 131-142.
30. BRIEVA JA, ROLDAN E, RODRIGUEZ C, NAVAS G. Human tonsil, blood and bone marrow in vivo-induced B cells capable of spontaneous and high-rate immunoglobulin secretion in vitro: differences in the requirements for factors and for adherent and bone marrow stromal cells, as well as distinctive adhesion molecule expression. Eur J Immunol 1994: 24: 362-366.